Context: Several randomized clinical trials (RCTs) have recently tested the early addition of docetaxel to androgen deprivation therapy (ADT) in hormone-sensitive metastatic prostate cancer (PCa). Objective: To perform a systematic review and meta-analysis of RCTs evaluating the combination of docetaxel and ADT in hormone-sensitive metastatic PCa. The primary end point was overall survival (OS). Secondary end point was progression-free survival. Exploratory subgroup analysis according to high-volume versus low-volume disease was performed. Evidence acquisition: A systematic review of PubMed/Medline, Embase, and the proceedings of major international meetings was performed in June 2015 and updated in August 2015. Three trials were selected for inclusion. Evidence synthesis: Overall, 2951 patients were included in the three trials. Two trials enrolled only metastatic patients; in the third trial, 61% were metastatic. A total of 2262 patients (951 docetaxel and ADT; 1311 ADT alone) were metastatic. Most patients had a good performance status. In metastatic patients, the addition of docetaxel was associated with improved OS (hazard ratio [HR]: 0.73; 95% confidence interval [CI], 0.60-0.90; p = 0.002), with nonsignificant heterogeneity among the three trials. Considering the whole study population (2951 patients), the addition of docetaxel was associated with a similar OS improvement (HR: 0.74; 95% CI, 0.61-0.91; p = 0.003). Although with limited statistical power, no significant interaction was demonstrated between the addition of docetaxel and the high or low volume of disease (p = 0.5). The addition of docetaxel was associated with improvement in progression-free survival (metastatic patients: HR: 0.63; 95% CI, 0.57-0.70; p < 0.001).
1.

Introduction
Prostate cancer (PCa) is the second most frequently diagnosed cancer in men and the second leading cause of cancer death in male patients in the United States and Europe [1] . Although localized PCa may be successfully treated with radical prostatectomy and external-beam radiation, many patients subsequently develop metastatic disease [2] . In the United States, the proportion of PCa patients presenting with advanced stage at first diagnosis is 4-5% for distant disease and 10-12% for regional disease [3] . Androgen deprivation therapy (ADT) by medical or surgical castration is the mainstay of treatment for locally advanced and metastatic PCa because the androgen receptor (AR) pathway plays a key role in the development and progression of PCa cells [4] . Although ADT is able to induce biochemical and clinical response in >90% of patients, after a median of 24-36 mo, patients experience progression to castration-resistant prostate cancer (CRPC), despite persisting low testosterone levels [5] .
Until very recently, chemotherapy with docetaxel was the only effective treatment for CRPC patients. The randomized clinical trial (RCT) TAX327 demonstrated that docetaxel plus prednisone prolonged overall survival (OS) compared with mitoxantrone plus prednisone [6] . Another RCT, the SWOG-9916 study, also demonstrated that treatment with docetaxel, estramustine, and dexamethasone increased median OS by 2 mo compared with mitoxantrone and prednisone [7] . Based on these results, docetaxel was the first cytotoxic drug to demonstrate OS improvement in PCa. More recently, several new agents have been introduced in clinical practice. Results from RCTs have demonstrated the efficacy of two new-generation hormonal therapies (abiraterone [8] and enzalutamide [9] ), an immunotherapy (sipuleucel-T [10] ), a new microtubuletargeting chemotherapy (cabazitaxel [11] ), and an aemitter (radium-223 [12] ), all able to prolong OS.
The progression of CRPC is now known to be due to the onset of a number of resistance mechanisms induced by the selective pressure of endocrine therapy [13] [14] [15] [16] [17] [18] . Castration is able to induce clonal selection and subsequent growth of androgen-independent cellular clones [19] . Hormone-sensitive PCa should be considered a heterogeneous disease, characterized by the coexistence of both AR-positive and AR-negative tumor cells.
In this biologic context, patients with hormone-sensitive PCa may benefit from chemotherapy in association with endocrine therapy, also targeting AR-negative cells and delaying the development of resistance mechanisms. In the pre-docetaxel era, several RCTs investigated the combination of endocrine therapy with other cytotoxic drugs in hormone-sensitive PCa patients, but none of these studies showed a significant and convincing advantage [20, 21] [24] , investigating the combination of docetaxel and ADT in hormone-sensitive disease, were made available to the scientific community.
The aim of this systematic review is to conduct a metaanalysis of RCTs that evaluated the combination of docetaxel with ADT versus ADT alone, in hormone-sensitive metastatic PCa, to assess the impact of this therapeutic option in terms of OS.
2.
Evidence acquisition [25, 26] were excluded. When more than one report of the same trial was available, the most recent information (corresponding to longer follow-up and higher number of events) was considered in the analysis. For each study, the quality of randomization was evaluated based on the information available in the publication [22, 23] or in the study protocol [24] .
Statistical methods
After data were abstracted, analysis was performed with the Review Manager software (RevMan v.5.3; The Nordic Cochrane Center, Copenhagen, Denmark). In all the trials included, efficacy data were analyzed from all randomly assigned patients on an intention-to-treat basis. Primary end point of the meta-analysis was OS. Secondary end point was biochemical progression-free survival (bPFS). Definition of bPFS was different in the three trials and is reported in Supplementary Table [ 
For both OS and bPFS, the summary measure was HR (with 95% CI). A random-effects model was applied. Statistical heterogeneity among studies was examined using the chi-square test and the I 2 statistic.
Main analysis was performed considering the three comparisons of docetaxel and ADT versus ADT alone. In one trial [24] , a further experimental arm was reported, testing the addition of docetaxel and zoledronic acid to ADT alone. Because the addition of zoledronic acid alone did not show any significant efficacy compared with ADT, we performed an exploratory analysis also adding this comparison to the analysis of docetaxel. However, because that trial used the same control arm for the two comparisons (docetaxel and ADT vs ADT alone, and docetaxel and zoledronic acid and ADT vs ADT alone), the weight of each comparison was reduced according to a correction factor equal to the number of events actually observed in the trial, divided by the number of events taken into account in the analysis (where the control arm was counted twice). This correction resulted in a prudential increase in the width of the CI for the estimated HR of each comparison.
For OS, the subgroup analysis of patients according to disease volume (high vs low volume) was available for two trials [23, 27] . In both trials, high-volume disease was defined as the presence of at least four bone lesions and at least one lesion in any bone beyond the spine/pelvis or the presence of visceral metastasis. Patients without these conditions were classified as low volume. No subgroup analysis of PFS according to disease volume was available.
2.4.
Role of funding source
There was no funding source for this review. All authors had full access to all the data, and the corresponding author (M.D.M.) had final responsibility for the decision to submit for publication.
Evidence synthesis
Characteristics and quality of the trials
The selection process of trials eligible for the meta-analysis is reported in Supplementary Figure 1 . In the search updated in August 2015, 464 of the 466 full-length published papers were excluded, and 2 (GETUG-AFU 15 and CHAARTED-[ 9 _ T D $ D I F F ] E3805) were found eligible for inclusion [22, 23] . Another eligible trial (STAMPEDE) was found searching the proceedings of the major international meetings [24] . An updated report of the already published GETUG-AFU 15 trial, with longer follow-up and a higher number of events for analysis, was available [27] . Table 1 lists the main characteristics of the three available trials. In all the trials, patients assigned to the experimental arm received docetaxel 75 mg/m 2 , for a maximum of six [23, 24] or nine cycles [22] . The maximum interval since the ADT start allowed to start docetaxel ranged from 2 to 4 mo. In the GETUG-AFU 15 trial, about half of the patients had started ADT within 15 d of enrollment [22] ; in the CHAARTED-[ 9 _ T D $ D I F F ] E3805 trial, median time from ADT to randomization was slightly >1 mo in both arms [23] .
According to the descriptions available in the publication [22, 23] or in the study protocol [24] , the quality of randomization process was judged adequate in all three trials.
Patient characteristics
Overall, 2951 patients were included in the three trials in the meta-analysis, 1181 (40%) assigned to docetaxel and ADT, and 1770 (60%) assigned to ADT alone ( Table 2 ). The main characteristics of the 2951 patients are described in Table 2 . Patients were enrolled between October 2004 and March 2013. Median age was 63-65 yr, and most patients had a good performance status. Two trials [22, 23] enrolled only metastatic patients; in the STAMPEDE trial [24] , metastatic patients were 61% of the total study population: overall, there were 2262 metastatic patients (951 docetaxel and ADT; 1311 ADT alone). Patients with metastatic disease at diagnosis were 71% in the GETUG-AFU 15 trial and 73% in the CHAARTED-[ 9 _ T D $ D I F F ] E3805 trial; in the STAMPEDE trial, 94% of patients had not received previous local therapy. Patients with high-volume disease were 48% in the GETUG-AFU 15 trial and 65% in the CHAARTED-[ 9 _ T D $ D I F F ] E3805 trial; this information was not available in the STAMPEDE trial.
Treatment compliance and toxicity
The median number of docetaxel cycles actually administered was eight in the GETUG-AFU 15 [22] , six in the CHAARTED-[ 9 _ T D $ D I F F ] E3805 [23] , and six in the STAMPEDE trial [24] . The proportion of patients completing the planned number of cycles was 48% in the GETUG-AFU 15 trial (nine planned cycles), 86% in the CHAARTED-
(six planned cycles), and 76% in the STAMPEDE trial (six planned cycles). The proportion of patients needing dose reduction was 11% in the GETUG-AFU 15 trial and 26% in the CHAARTED-[ 9 _ T D $ D I F F ] E3805 trial; this information was not available in the report of the STAMPEDE trial. Most common adverse events reported with the addition of docetaxel were hematologic toxicity (anemia, thrombocytopenia, and neutropenia), fatigue, gastrointestinal toxicity (nausea, vomiting, constipation, and diarrhea), alopecia, sensory neuropathy, stomatitis/mucositis, nail changes, and peripheral edema. In all three trials, the addition of docetaxel was associated with a higher incidence of febrile neutropenia: 8%, 6%, and 12% in the GETUG-AFU 15, CHAARTED-[ 9 _ T D $ D I F F ] E3805, and STAMPEDE trials versus 0%, not reported, and 1% with ADT alone in the three trials, respectively. Median follow-up 82.9 mo 28.9 mo NA ADT = androgen deprivation therapy; ECOG = Eastern Cooperative Oncology Group; IV = intravenous; LHRH = luteinizing hormone-releasing hormone; NA = not available; OS = overall survival; PCa = prostate cancer; PSA = prostate-specific antigen; WHO = World Health Organization. * After amendment. In the initial protocol version, only high-volume patients were eligible.
3.4.
Overall survival Table 3 summarizes the number of events and OS data reported in each trial. Overall, 916 deaths were recorded for the main comparison (docetaxel and ADT vs ADT alone) in metastatic patients. As shown in Figure 1A , the addition of docetaxel to ADT in metastatic patients was associated with a statistically significant OS benefit (HR: 0.73; 95% CI, 0.60-0.90; p = 0.002). There was no evidence of statistically significant heterogeneity among the three trials (p = 0.15; I 2 = 48%). In the whole study population, including also the minority of nonmetastatic patients (Fig. 1B) , the addition of docetaxel to ADT was associated with a similar, statistically significant OS benefit (HR: 0.74; 95% CI, 0.61-0.91; p = 0.003). Very similar results were obtained in the exploratory analysis also including the docetaxel and zoledronic acid arm of the STAMPEDE trial: HR 0.74 (95% CI, 0.63-0.88; p < 0.001) considering only metastatic 
patients (Fig. 1C) , HR 0.76 (95% CI, 0.64-0.89; p = 0.001) in all patients (Fig. 1D ). (Fig. 2) . The test for difference of efficacy among the two subgroups did not demonstrate a statistically significant interaction (p = 0.5). The HR for the addition of docetaxel to ADT was 0.67 (95% CI, 0.51-0.88) in patients with high-volume disease and 0.80 (95% CI, 0.49-1.32) in patients with lowvolume disease.
Subgroup analysis was performed for metastatic patients with high-volume and low-volume disease enrolled in the GETUG-AFU 15 and in the CHAARTED-[ 9 _ T D $ D I F F ] E3805 trial
Progression-free survival
As shown in Figure 3A , the addition of docetaxel to ADT in metastatic patients was associated with a statistically significant benefit in PFS (HR: 0.63; 95% CI, 0.57-0.70; p < 0.001) without significant heterogeneity among the three trials (p = 0.7; I 2 = 0%). The same benefit was shown considering the whole study population including the minority of patients without metastases (HR: 0.63; 95% CI, 0.57-0.70; p < 0.001) (Fig. 3B) . Very similar results were obtained in the exploratory analysis including also the docetaxel and zoledronic acid arm of the STAMPEDE trial: HR: 0.63 (95% CI, 0.56-0.70; p < 0.001) in metastatic patients (Fig. 3C) , HR 0.63 (95% CI, 0.57-0.70; p < 0.001) in all patients (Fig. 3D ).
Discussion
This meta-analysis shows that the addition of docetaxel to ADT in patients with metastatic hormone-sensitive PCa is associated with a significant improvement in OS and PFS. A quantitative synthesis of the evidence currently available about this treatment strategy can be really helpful for clinical decisions because three recent phase 3 trials (GETUG-AFU-15 [22, 27] , CHAARTED-[ 9 _ T D $ D I F F ] E3805 [23] , and STAMPEDE [24] ) tested the activity of docetaxel in combination with endocrine therapy in the relatively early setting of hormone-sensitive PCa. To the best of our knowledge, no other trials have been conducted with docetaxel in the same setting, and this meta-analysis represents the synthesis of all the evidence produced to date. Notably, in the GETUG-AFU-15 trial, the first trial to be published, the concomitant administration of docetaxel with ADT versus ADT alone did not show a significant OS benefit [22, 27] . On the contrary, the CHAARTED-[ 9 _ T D $ D I F F ] E3805 trial showed a significant OS improvement for ADT plus docetaxel [23] , adding fuel to the scientific debate about the opportunity of this therapeutic option in hormonesensitive PCa patients. In our meta-analysis that also included the recent results of the ''third comer,'' the STAMPEDE trial [24] , the addition of docetaxel to ADT in metastatic patients was associated with a statistically significant increase in OS, with a moderate nonsignificant heterogeneity among the three RCTs. Of note, the absence of statistical heterogeneity increases the validity of the result, allowing a global, unambiguous interpretation of all the evidence available. Of course, a meta-analysis based on individual patient data (IPD) would represent the best synthesis of evidence, allowing for data checking, updated follow-up compared with publications, calculation and comparison of times to events, and investigation of treatment heterogeneity in subgroups [28] . However, in the absence of an IPD meta-analysis, a meta-analysis based on abstracted data can be considered an acceptable surrogate, allowing a timely synthesis of all the available trials.
The efficacy demonstrated by docetaxel in combination with ADT in hormone-sensitive patients is not surprising, due to its strong biologic basis. Recent evidence shows that one of the mechanisms responsible for progression from ADT plus docetaxel vs ADT alone 0.9 (0.7-1. 
hormone-sensitive to the castration-resistant phase of disease is the clonal selection and proliferation of preexisting AR-independent cells, able to survive in a low androgen level environment [19] . Therefore it is reasonable to assume that, since its onset, PCa is a heterogeneous disease where AR-positive and AR-negative cells coexist [19, 29] . Both these cellular clones are likely involved in progression to castration-resistant disease [19] . Docetaxel administration concurrent to ADT in hormone-sensitive PCa patients allows the inhibition of the growth of the preexisting ARinsensitive clones, killing these cells earlier when they are still a small number and before the development of multiple escape mechanisms. Preclinical data show that the adaptive response to ADT by PCa cells is mediated by both ligand-dependent AR activation and ligand-independent AR activation and by mechanisms of progression bypassing AR signaling [19, 30] . Taxanes are able to interfere with several steps of these resistance mechanisms. Emerging preclinical data demonstrated that taxanes could inhibit the AR signaling pathway [31] . These cytotoxic drugs interfere with polymerization of microtubules, blocking AR nuclear translocation and AR-induced gene expression [31, 32] . Therefore docetaxel could act synergistically with endocrine therapy because it impairs AR activity [31, 32] . Chemotherapy may also kill cells that escape ADT through activation of ARindependent survival pathways [33] .
From a clinical point of view, administering chemotherapy to metastatic PCa patients in an early phase of the disease has several potential advantages. In the hormone-sensitive setting, patients are, on average, in better clinical condition compared with the castrationresistant setting, due to a lower burden of disease. Consequently, they are able to better tolerate chemotherapy and to maintain adequate drug dose intensity. More patients are eligible for chemotherapy, whereas in the castration-resistant setting a relevant number of patients cannot receive chemotherapy due to worsening performance status and clinical conditions.
Our meta-analysis shows an OS improvement that is not only statistically significant but also clinically relevant. The addition of docetaxel to ADT is associated with a 27% reduction in the risk of death of metastatic patients (HR: 0.73), and the reduction in the risk of death is 33% in patients with high-volume disease (HR: 0.67). In absolute terms, this magnitude of benefit is rarely obtained in the setting of advanced solid tumors: the difference in median OS for metastatic patients was >13 mo in the CHAARTED- [23] and 18 mo in the STAMPEDE trial [24] . Much smaller benefits have been often judged sufficient to change clinical practice in metastatic PCa, as well as in other settings. However, we recognize that a careful selection of patients to be treated with upfront docetaxel is essential for a favorable benefit-risk ratio. Subgroup data of the CHAARTED trial have suggested that the benefit associated with concomitant administration of docetaxel with ADT, at least in an early analysis, was more pronounced in patients with high-volume disease than in patients with low-volume disease [23] . Definition of high-volume disease follows previous robust data showing that, in patients with hormone-sensitive disease, the presence of extensive disease (visceral metastases or appendicular skeletal involvement) is related to a worse prognosis [34] [35] [36] . In both the CHAARTED-[ 9 _ T D $ D I F F ] E3805 (based on a prospective definition) and the GETUG-AFU 15 (based on a retrospective assessment) trials, high-volume disease was defined as the presence of visceral metastases or the presence of at least four bone lesions, with one or more lesions in any bone beyond the spine/pelvis. However, based on subgroup data available for those two trials [23, 27] , we performed an exploratory analysis of treatment efficacy according to disease volume. Although the statistical test for interaction is characterized by a limited statistical power, we did not demonstrate a significant interaction between disease volume and treatment efficacy. Importantly, this absence of significant interaction does not allow us to state that the addition of docetaxel to ADT is not effective in patients with low-volume metastatic disease. A longer follow-up with a higher number of events, together with the availability of this subgroup analysis also in the STAMPEDE trial, could increase the statistical power of the analysis. With the currently available evidence, however, no definitive statement can be made about the interaction between docetaxel efficacy and disease volume.
With the exception of a subgroup of patients in the STAMPEDE trial, most patients included in the three trials had metastatic disease. Other trials have tested the efficacy of the addition of docetaxel to ADT in patients with highrisk localized PCa [25, 26] . However, the definition of the role of docetaxel in patients with high-risk localized PCa is beyond the scope of this meta-analysis. Particular attention should be given to toxicity associated with combination treatment. In the experimental arm of GETUG-AFU 15 study, four treatment-related deaths were reported (one due to febrile neutropenia, one neutropenia with infection, one multiorgan failure, and one pulmonary embolism), compared with no treatment-related deaths with ADT alone [22] . In the CHAARTED-[ 9 _ T D $ D I F F ] E3805 trial, only one treatment-related death (sudden death) occurred in the combination arm [23] . Although these numbers, considered overall, are quite reassuring, it is well known that patients enrolled in clinical trials are selected compared with all patients treated in daily clinical practice in terms of age, performance status, and comorbidities. For instance, patients aged >70 yr are a relevant proportion in clinical practice but were quite underrepresented in the three trials. In the CHAARTED trial, subgroup analysis according to age[ 3 _ T D $ D I F F ] supports docetaxel efficacy[ 1 7 _ T D $ D I F F ] also in elderly patients, but they represented only 23% of the total study population [23] . Although a potential explanation is that the age of metastatic presentation of patients eligible for these three trials could be younger than the whole population of patients with a new diagnosis of earlier stage PCa, we believe the main reason for the underrepresentation of elderly patients in the trials included in this metaanalysis is the selection bias because patients had to be fit enough to receive chemotherapy with docetaxel [37] . In any case, chemotherapy toxicity is often worse in the real-world population compared with the toxicity reported in clinical trials. Therefore, clinicians must take into account some relevant clinical factors (performance status, concomitant diseases) before considering the addition of docetaxel to ADT, to reduce the risk of severe toxicity that could negatively affect quality of life and, in worst cases, survival.
Conclusions
In conclusion, our meta-analysis clearly shows a significant impact on OS with the concomitant administration of docetaxel and ADT in patients with metastatic hormonesensitive PCa. Considering the absence of heterogeneity among the available trials, and the balance between magnitude of efficacy and risk of toxicity, the combination of chemotherapy and hormonal treatment should be reasonably offered to patients with metastatic disease, if judged eligible for chemotherapy. Higher statistical power would be needed to better understand the interaction, if any, between the efficacy of docetaxel and the volume of disease.
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